Summary & Overview
HCPCS C9174: Injection, datopotamab deruxtecan-dlnk, 1 mg
HCPCS Level II code C9174 denotes a 1 mg unit of datopotamab deruxtecan-dlnk, an antibody–drug conjugate used in oncology. As a newly codified HCPCS Level II injectable drug code, C9174 matters nationally because it standardizes unit-based billing for hospital outpatient departments, oncology clinics, and ambulatory infusion centers, facilitating consistent claims submission and pricing transparency for high-cost targeted therapies. Major payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the drug, typical sites of service and service type, and coverage considerations across national payers. The publication also summarizes billing benchmarks, common modifier practice, and policy developments relevant to unit-based HCPCS drug coding. Where available, the report highlights pricing and reimbursement patterns, documentation expectations for oncology injectables, and operational implications for outpatient infusion centers and hospital billing departments. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code C9174 describes an injection of datopotamab deruxtecan-dlnk, 1 mg. This code represents a single milligram unit of a targeted antibody–drug conjugate administered via injection. The service type is an injectable oncology therapeutic, typically delivered as an outpatient infusion or injection in settings such as hospital outpatient departments, oncology clinics, or ambulatory infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic or unresectable HER2-expressing solid tumor receiving targeted antibody–drug conjugate therapy. The patient presents to an outpatient oncology infusion center for administration of C9174 — datopotamab deruxtecan-dlnk, dosed and billed per milligram. Clinical workflow includes verification of diagnosis and prior authorization, chemotherapy education and consent, baseline vital signs and laboratory review (hematology, hepatic and renal panels), insertion or assessment of vascular access (peripheral IV or implanted port), preparation of the agent in pharmacy under aseptic technique, administration by an oncology nurse with standard infusion monitoring, and post-infusion observation for infusion-related reactions. Documentation includes indication, dose (mg) administered, lot number, infusion start/stop times, premedications, patient tolerance, and any adverse events. Typical follow-up includes scheduled oncology visits for response assessment and interval labs to monitor toxicity and dose adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
52 | Reduced services | Use when the dose or service is partially reduced or truncated (e.g., lower-than-standard mg administered for clinical reasons). |
53 | Discontinued procedure | Use when the infusion is started but discontinued due to patient intolerance or adverse reaction before completion.